BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY

被引：0
|
作者：
Lee, Yeonhu [1 ]
Roh, Tae Hoon [1 ]
Kim, Se-Hyuk [1 ]
机构：
[1] Ajou Univ, Sch Med, Ajou Univ Hosp, Dept Neurosurg, 164 World Cup Ro, Suwon, Kyonggi Do, South Korea
来源：
NEURO-ONCOLOGY | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NCOG-08
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study
    Lee, Yeonhu
    Lee, Eunyoung
    Roh, Tae Hoon
    Kim, Se-Hyuk
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (34)
  • [2] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    [J]. NEURO-ONCOLOGY, 2023, 25
  • [3] Bevacizumab plus irinotecan in recurrent glioblastoma
    Chamberlain, Marc C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 1012 - 1013
  • [4] Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma
    Simoes, J.
    Tavares, N. T.
    Borges, C.
    Meireles, S.
    Fernandes, C.
    Costa, A.
    Caeiro, C.
    Damasceno, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
    Friedman, Henry S.
    Prados, Michael D.
    Wen, Patrick Y.
    Mikkelsen, Tom
    Schiff, David
    Abrey, Lauren E.
    Yung, W. K. Alfred
    Paleologos, Nina
    Nicholas, Martin K.
    Jensen, Randy
    Vredenburgh, James
    Huang, Jane
    Zheng, Maoxia
    Cloughesy, Timothy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4733 - 4740
  • [6] Bevacizumab plus irinotecan in recurrent glioblastoma - Reply
    Vredenburgh, James J.
    Desjardins, Annick
    Reardon, David A.
    Friedman, Henry S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 1013 - 1013
  • [7] Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    Vredenburgh, James J.
    Desjardins, Annick
    Herndon, James E., II
    Marcello, Jennifer
    Reardon, David A.
    Quinn, Jennifer A.
    Rich, Jeremy N.
    Sathornsumetee, Sith
    Gururangan, Sridharan
    Sampson, John
    Wagner, Melissa
    Bailey, Leighann
    Bigner, Darell D.
    Friedman, Allan H.
    Friedman, Henry S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4722 - 4729
  • [8] PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Cloughesy, Tim
    Finocchiaro, Gaetano
    Belda-Iniesta, Cristobel
    Recht, Lawrence
    Brandes, Alba A.
    Pineda, Estela
    Mikkelsen, Tom
    Chinot, Olivier
    Balana, Carmen
    Macdonald, David
    Westphal, Manfred
    Hopkins, Kirsten
    Weller, Michael
    Bruey, Jean-Marie
    Liu, Bo
    Verret, Wendy
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [9] BEVACIZUMAB AND IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
    Naskhletashvili, D. R.
    Gorbounova, V.
    Bychkov, M.
    Bekyashev, A.
    Karakhan, V.
    Aloshin, V.
    Fu, R.
    Moskvina, E.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 59 - 59
  • [10] Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
    Nayak, Lakshmi
    Molinaro, Annette M.
    Peters, Katherine
    Clarke, Jennifer L.
    Jordan, Justin T.
    de Groot, John
    Nghiemphu, Leia
    Kaley, Thomas
    Colman, Howard
    McCluskey, Christine
    Gaffey, Sarah
    Smith, Timothy R.
    Cote, David J.
    Severgnini, Mariano
    Yearley, Jennifer H.
    Zhao, Qing
    Blumenschein, Wendy M.
    Duda, Dan G.
    Muzikansky, Alona
    Jain, Rakesh K.
    Wen, Patrick Y.
    Reardon, David A.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1048 - 1057
12345